Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
University of California, Irvine
Thomas Jefferson University
Mayo Clinic
Humanetics Corporation
Swiss Cancer Institute
Spanish Lung Cancer Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Swiss Cancer Institute
Fox Chase Cancer Center
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Spectrum Pharmaceuticals, Inc
University of Colorado, Denver
UNICANCER
Odense University Hospital
Medstar Health Research Institute
Case Comprehensive Cancer Center
NYU Langone Health
Abramson Cancer Center at Penn Medicine
Canadian Cancer Trials Group
University of Wisconsin, Madison
M.D. Anderson Cancer Center
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Swiss Cancer Institute
Wake Forest University Health Sciences
Abramson Cancer Center at Penn Medicine
Abramson Cancer Center at Penn Medicine
Radiation Therapy Oncology Group
Wake Forest University Health Sciences
Radiation Therapy Oncology Group
City of Hope Medical Center
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
Roswell Park Cancer Institute
Stanford University
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Swedish Orphan Biovitrum